Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern cooperative oncology group study

✍ Scribed by Ettinger, David S. ;Finkelstein, Dianne M. ;Donehower, Ross C. ;Chang, Alex Y. C. ;Green, Michael ;Blum, Ronald ;Hahn, Richard G. ;Ruckdeschel, John C.

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: English
• Weight: 407 KB
• Volume: 17
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950170306

✦ Synopsis

One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with spirogermanium and 4-demethoxydaunorubicin. There were eight life-threatening complications (mostly hematologic) and two lethal complications (N-MF, hematologic; 4-demethoxydaunorubicin, gastrointestinal). The overall survival ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were associated with poor survival: Poor initial performance status, prior weight loss, presence of liver or subcutaneous metastases.